Drug Profile

ZY 19489

Alternative Names: ZY19489

Latest Information Update: 11 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cadila Healthcare
Developer Zydus Lifesciences
Class Antimalarials
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Malaria
New Molecular Entity Yes

Highest Development Phases

Phase I Malaria

Most Recent Events

11 Dec 2025 ZY 19489 is still in phase I trials for Malaria (In Volunteers) in India and Australia (PO)
22 Jun 2023 Zydus Lifesciences plans a phase I trial for Falciparum malaria (Combination therapy, In adults) in July 2023 (PO) (NCT05911828)
03 Feb 2022 ZY 19489 receives Orphan Drug status for Malaria in USA, prior to February 2022

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com